BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
We have analyzed brain and acute leukemia, cytoplasmic (BAALC) gene expression and other genetic markers (ERG, EVI1, MN1, PRAME, WT1, FLT3, and NPM1 mutations) in 127 intermediate-risk acute myeloid leukemia (AML) patients: 98 cytogenetically normal and 29 with intermediate-risk cytogenetic alterations. High versus low BAALC expressers showed a higher refractoriness to induction treatment (31% vs 10%; p = .005), lower complete remission rate after salvage therapy (82% vs 97%; p = .010), and lower 3-year overall (23% vs 58%, p < .001) and relapse-free survival (26% vs 52%, p = .006). Similar results were found when cytogenetic subgroups were analyzed separately. Multivariate models confirmed the unfavorable prognosis of this marker. In conclusion, BAALC is a relevant prognostic marker in intermediate-risk AML.
Santamaría
Carlos
C
Hospital Universitario, Salamanca, Spain. cmsantamaria@usal.es
Chillón
María C
MC
García-Sanz
Ramón
R
Pérez
Cristina
C
Caballero
María D
MD
Mateos
María V
MV
Ramos
Fernando
F
de Coca
Alfonso García
AG
Alonso
José M
JM
Giraldo
Pilar
P
Bernal
Teresa
T
Queizán
José A
JA
Rodríguez
Juan N
JN
Puig
Noemí
N
Balanzategui
Ana
A
Sarasquete
María E
ME
Alcoceba
Miguel
M
Díaz-Mediavilla
Joaquín
J
San Miguel
Jesús
J
González
Marcos
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D000090243:Nucleophosmin; D011237:Predictive Value of Tests; D012307:Risk Factors; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; C442828:BAALC protein, human; D014408:Biomarkers, Tumor; C000716967:NPM1 protein, human; D009363:Neoplasm Proteins; D000090243:Nucleophosmin